Bon Natural Life Ltd BON
Medicinal Chemicals and Botanical Products · IPO 2021 · data as of November 13, 2026
Bon Natural Life Ltd (BON) is a healthcare company listed in the US with a market value of about $9M. In fiscal year 2025 it had revenue of $19M and net income of -$2M, a net margin of -10.7%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 66.6, 5-year revenue growth of 0% a year, a 5-year average ROIC of 9%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 88% below the current price.
About Bon Natural Life
Bon Natural Life is listed in the US and classified in medicinal chemicals and botanical products, IPO year 2021. Revenue went from $16M in 2019 to $19M in 2025, growth of about 2.2% a year. It was profitable in 6 of the last 7 years in our data. It spends 4% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- More cash than debt, or low debt to equity
- Positive free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $19M | $24M | $30M | $30M | $25M | $18M | $16M |
| Net income | -$2M | $398172 | $5M | $6M | $5M | $3M | $3M |
| Free cash flow | $134288 | -$8M | -$678810 | -$214816 | $4M | $3M | $7M |
| EPS (diluted) | $-0.25 | $0.05 | $0.57 | $0.77 | $0.56 | $0.37 | $0.32 |
| Net margin | -10.7% | 1.7% | 15.6% | 20.9% | 18.0% | 16.6% | 15.7% |
| ROIC | -2.1% | 2.1% | 13.1% | 16.9% | 15.9% | 20.4% | 37.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Bon Natural Life stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 88% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Bon Natural Life pay a dividend?
Not currently.
Is Bon Natural Life a good stock to buy?
We do not give buy or sell advice. Bon Natural Life scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.